Aarey Drugs & Pharmaceuticals Ltd

At Rs 75.39, sellers were still queuing — but there were no buyers willing to take the other side. Aarey Drugs & Pharmaceuticals Ltd locked at its lower circuit of 5% on 16 Jun 2026, with unfilled sell orders and a frozen price, signalling a day dominated by supply overwhelming demand.

Aarey Drugs & Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

At Rs 74.51, sellers were still queuing — but there were no buyers willing to take the other side. Aarey Drugs & Pharmaceuticals Ltd locked at its lower circuit of 5% on 11 Jun 2026, with unfilled sell orders and a frozen price, signalling persistent selling pressure in a micro-cap stock.

Aarey Drugs & Pharmaceuticals Ltd has witnessed a notable transformation in its valuation metrics, shifting from a previously risky profile to one deemed attractive by recent assessments. This change, coupled with a significant upgrade in its Mojo Grade from Strong Sell to Hold, underscores a renewed investor interest and a potential re-rating of the micro-cap pharmaceutical player amid a challenging sector backdrop.

Aarey Drugs & Pharmaceuticals Ltd has demonstrated a notable financial turnaround in the quarter ended March 2026, reversing a previously negative trend with its highest quarterly revenue and profit metrics to date. This improvement has prompted an upgrade in its Mojo Grade from Strong Sell to Sell, signalling cautious optimism amid ongoing market challenges.

Aarey Drugs & Pharmaceuticals Ltd. reported a dramatic revenue surge in Q4 FY26, with net sales jumping 96.48% quarter-on-quarter to ₹189.47 crores—the highest quarterly figure in recent history. However, the impressive topline growth failed to translate into meaningful bottom-line expansion, as net profit stood at ₹1.56 crores, up 173.68% QoQ but still reflecting wafer-thin margins. The micro-cap pharmaceutical company, with a market capitalisation of ₹222.00 crores, continues to grapple with structural profitability challenges despite strong revenue momentum.

Aarey Drugs & Pharmaceuticals Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 29 May 2026, reflecting a complex interplay of deteriorating fundamental metrics and nuanced technical signals. Despite recent positive quarterly results, the company’s long-term financial health and valuation concerns have weighed heavily on investor sentiment, prompting a reassessment of its outlook within the Pharmaceuticals & Biotechnology sector.

Aarey Drugs & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 14 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 May 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

At Rs 81.12, sellers were still queuing — but there were no buyers willing to take the other side. Aarey Drugs & Pharmaceuticals Ltd locked at its lower circuit of 5% on 20 May 2026, with unfilled sell orders and a frozen price.

Aarey Drugs & Pharmaceuticals Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 14 May 2026, driven primarily by a marked improvement in technical indicators. However, the company continues to face significant challenges on the fundamental front, with weak financial performance and deteriorating promoter confidence. This article analyses the four key parameters—Quality, Valuation, Financial Trend, and Technicals—that influenced this rating change, providing investors with a comprehensive view of the stock’s current standing.

The 50-day moving average for Aarey Drugs & Pharmaceuticals Ltd has crossed above the 200-day moving average, creating a golden cross on 14 May 2026. While this technical event often signals a shift towards bullish momentum, the broader technical and fundamental context presents a more nuanced picture that merits careful analysis.

Aarey Drugs & Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 28 Nov 2025, reflecting a change from a previous 'Sell' rating. However, all fundamentals, returns, and financial metrics discussed here are current as of 09 May 2026, providing an up-to-date view of the stock's position in the market.

At Rs 86.00, sellers were still queuing — but there were no buyers willing to take the other side. Aarey Drugs & Pharmaceuticals Ltd locked at its lower circuit of 4.98% on 30 Apr 2026, with unfilled sell orders and a frozen price.

At Rs 91.11, Aarey Drugs & Pharmaceuticals Ltd locked at its lower circuit on 29 Apr 2026, reflecting a 4.29% decline within a 5% price band. Sellers were lined up to exit, but buyers were absent, resulting in unfilled supply and a frozen price that underscores the liquidity challenges faced by this micro-cap stock.

Aarey Drugs & Pharmaceuticals Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 28 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 April 2026, providing investors with an up-to-date view of the company's fundamentals, valuation, financial trends, and technical outlook.